BenevolentAI Results Presentation Deck
Cash runway to Q4-2024 providing sufficient capital for
key value inflection points
Cash Runway
Cash¹ at 31 December 2022
£130.2m
2022 cash burn of £64.7m before working
capital movements
Cash runway guidance assumes no future
capital from licensing or collaboration
agreements
Multiple assets at, or close to, key value
inflection points
1) Includes cash, cash equivalents and short-term deposits (maturity
between 3 and 12 months).
Benevolent
3
5
Capital allocation
Fund Phase I trial for BEN-8744 in Ulcerative Colitis and
commencement of Phase II trial in 2024
Fund CTA enabling work for BEN-28010 and begin Phase I
trial in GBM in 2024
Progress balance of pipeline as well as fund CTA enabling
work of novel ALS asset to complete in 2024
Continuous enhancement of the Benevolent Platform™
to support further collaborations
Business Operations to support Group activities
BenevolentAl Proprietary
Benevolent 13View entire presentation